

Centers for Disease Control and Prevention National Institute for Occupational Safety and Health Robert A. Taft Laboratories 4676 Columbia Parkway Cincinnati, OH 45226-1998

October 23, 2013

J.T.J. Stouten
The Health Council of the Netherlands
PO Box 16052
2500 BB The Hague
The Netherlands

Dear Mr. Stouten:

Thank you for the opportunity to review the draft report on *Ifosfamide* prepared by the Subcommittee on the Classification of Carcinogenic Substances of the Dutch Expert Committee on Occupational Safety (DECOS), a subcommittee of the Health Council of the Netherlands.

If you have any questions regarding the comments, please contact me at 513-533-8260 (telephone) or by Email at tbl7@cdc.gov.

Sincerely yours,

Гhomas J. Lentz, Ph.D., M.P.H.

Branch Chief

Document Development Branch Education and Information Division

1 Enclosure

Review comments on Ifosfamide draft document by David Murray and Samy Rengasamy, NIOSH/NPPTL, 626 Cochrans Mill Road, Pittsburgh, PA 15236; Kristine Krajnak, NIOSH/HELD, 1095 Willowdale Road, Morgantown, WV 26506; and Clayton B'Hymer, NIOSH/DART, 4676 Columbia Parkway, Cincinnati, OH 45226

4676 Columbia Parkway, Cincinnati, OH 45226	
SECTION & PARAGRAPH	COMMENT
General Comments	Agree with the three classifications. Presumed
	human reproductive toxicant for effects on
	fertility and development, insufficient data for
	effects via lactation.
	Document seems to be accurate and the studies
	used as supporting data represent what is known
	regarding the literature.
	The chemical listed is presumed to be a
	reproductive hazard and should stay that
	way. There is a developed literature that
	addresses the occupational hazard of
	antineoplastic drugs; however, the references are
·	not specific to ifosfamide.
	There are no references that describe the use of
	personal protective equipment (PPE). Ifosfamide
	is handled as an aqueous solution that is typically
	injected intravenously or intraperitoneally or
	given orally. Some references not included
· ·	describe detecting residue left on surfaces as a
	means of accessing exposure for medical workers
	or cleaning staff thus suggesting that this might be
	a dermal or respiratory source for exposure.
	There is a surprisingly wide gap between human
	intravenous dose and animal dose. Could this be
	due to a daily vs. accumulative dose? Also, it is
	amazing that significant effects are noticed at the
	lower animal dosage, but effects in higher doses
	in humans were minimal, which suggests that the
	human data may not be adequate.
	Might consider adding references describing
	occupational exposure to antineoplastic drugs
	although there is no specific information on
·	ifosfamide. Example:
	Evaluation of working practices and surface
ĺ	contamination with antineoplastic drugs in
	outpatient oncology health care settings, Kopp,
	B; Schierl, R; Nowak, D International Archives
	Of Occupational And Environmental Health
	Volume:86 Issue:1 Pages:47-55
·	DOI: 10.1007/s00420-012-0742-z January 2013

Specific Comments	
Section 2.2	The reference to Longhi et al. should also include the book chapter published by the same authors. It covers the same material, but would be useful if readers could not find the 2003 journal article. The book chapter reference is as follows: Longhi A, Vitali G, Macchiagodena M, Bacci G, Fertility in males and females osterosarcoma patients treated with chemotherapy, in Trends in Bone Cancer Research, Vol. 24, Birch EV editor, 2006, Nova Science Publishing, New York, pp. 247-263.
Page 8, last paragraph	It has been stated that oral administration of ifosfamide produced unacceptable neurotoxicity because oral bioavailability is close to 100%. It looks like intravenous administration will also produce similar toxicity. This point is not described well.
Page 9, Para 1	Total body clearance of ifosfamide is presented as 3.6-8.9 L/h. Please make sure that clearance is presented in the appropriate unit.
Page 13, Para 3	Ehling et al (1998) conducted mutation studies with ifosfamide i.p. administration. After successful matings, females were sacrificedlive and dead implantations; results for this description appears to be missing.